Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025290 | 0.88 | CNR1 (0.46) | CNR2CNR1APLNR | |
| SCHEMBL28296806 | 0.84 | APLNR (0.42) | CNR2CNR1APLNRTHRATHRB | |
| SCHEMBL2046234 | 0.84 | PPARA (0.52) | CNR2CNR1THRATHRB | |
| SCHEMBL1229002 | 0.82 | DHFR (0.53) | CNR2CNR1 | |
| SCHEMBL2019712 | 0.82 | CNR2 (0.45) | CNR2CNR1THRATHRB | |
| SCHEMBL31614853 | 0.82 | CNR2 (0.45) | CNR2CNR1THRATHRB | |
| SCHEMBL22589091 | 0.81 | CNR2 (0.51) | CNR2CNR1THRATHRB | |
| SCHEMBL1552422 | 0.81 | PDCD1 (0.40) | CNR2CNR1APLNRTHRATHRB | |
| SCHEMBL16301494 | 0.81 | PDE3B (0.43) | CNR2CNR1APLNRTHRATHRB | |
| SCHEMBL120379 | 0.81 | DHFR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | claimed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | claimed |
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | disclosed |
| US-9334302-B2 | Method for removing FMOC group | AJINOMOTO CO., INC. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9206230-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140371424-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8859732-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | AJINOMOTO CO., INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | CNR2 4682/4885CNR1 4670/4885APLNR 419/4885 |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | CNR2 4197/4885CNR1 4108/4885APLNR 263/4885 |
| US-20110160433-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | CNR2 2139/4885CNR1 2142/4885APLNR 867/4885 |
| US-20140371424-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | CNR2 2139/4885CNR1 2142/4885APLNR 867/4885 |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | ESD, HM13, FURIN | CNR2 2710/4885CNR1 3237/4885APLNR 2304/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | CNR2 4197/4885CNR1 4108/4885APLNR 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.